Alemtuzumab
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.

It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.

Alemtuzumab was approved for medical use in the United States in 2001. (Mab)Campath was withdrawn from the markets in the US and Europe in 2012, to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.
Q12140
medication
Concept
Q1088156
chronic lymphocytic leukemia
Concept
Q8277
multiple sclerosis
Concept
Q640448
injection into a vein
Concept
Q422248
monoclonal antibody
Concept
Q21108353
CD52
MISC
Q715347
lymphocyte
Concept
Q48196
stem cell
Concept
Q420164
Alemtuzumab
Concept
Q420164
Alemtuzumab
Concept
2001-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2001
DATE
2012-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2012
DATE
+52^^http://www.w3.org/2001/XMLSchema#decimal
52
NUMBER
+52^^http://www.w3.org/2001/XMLSchema#decimal
52
NUMBER
instance of
medical condition treated
medical condition treated
instance of